fluorobenzenes has been researched along with mocetinostat in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bulhak, AA; Gonon, AT; Gourine, AV; Pernow, J; Sjöquist, PO; Valen, G | 1 |
| Budinsky, A; Resch, U; Sinzinger, H; Tatzber, F | 1 |
| Handa, O; Ichikawa, H; Isozaki, Y; Katada, K; Kokura, S; Naito, Y; Takagi, T; Tsuboi, H; Yoshida, N; Yoshikawa, T | 1 |
| Andreou, I; Dimopoulos, MA; Gounari, P; Miliou, A; Papadimitriou, CA; Papageorgiou, N; Siasos, G; Stefanadis, C; Tentolouris, C; Tousoulis, D; Zisimos, K | 1 |
| Andreou, I; Dimopoulos, MA; Miliou, A; Papadimitriou, CA; Papageorgiou, N; Siasos, G; Stefanadis, C; Tentolouris, C; Tousoulis, D; Tsiatas, M | 1 |
3 trial(s) available for fluorobenzenes and mocetinostat
| Article | Year |
|---|---|
Reduction of oxidative stress and modulation of autoantibodies against modified low-density lipoprotein after rosuvastatin therapy.
Topics: Antioxidants; Autoantibodies; Biomarkers; Copper; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoglobulin G; Immunoglobulin M; Lipoproteins, LDL; Male; Malondialdehyde; Middle Aged; Oxidation-Reduction; Oxidative Stress; Peroxidase; Peroxides; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2006 |
Effects of rosuvastatin on myeloperoxidase levels in patients with chronic heart failure: a randomized placebo-controlled study.
Topics: Aged; Allopurinol; Biomarkers; Cholesterol; Cholesterol, LDL; Chronic Disease; Female; Fluorobenzenes; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Peroxidase; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Triglycerides | 2010 |
Effects of rosuvastatin and allopurinol on circulating endothelial progenitor cells in patients with congestive heart failure: the impact of inflammatory process and oxidative stress.
Topics: AC133 Antigen; Aged; Allopurinol; Antigens, CD; Antigens, CD34; Endothelial Cells; Enzyme Inhibitors; Female; Fluorobenzenes; Glycoproteins; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Middle Aged; Oxidative Stress; Peptides; Peroxidase; Pyrimidines; Rosuvastatin Calcium; Stem Cells; Sulfonamides; Vascular Endothelial Growth Factor Receptor-2; Xanthine Oxidase | 2011 |
2 other study(ies) available for fluorobenzenes and mocetinostat
| Article | Year |
|---|---|
Oral pre-treatment with rosuvastatin protects porcine myocardium from ischaemia/reperfusion injury via a mechanism related to nitric oxide but not to serum cholesterol level.
Topics: Administration, Oral; Animals; Blood Pressure; Cholesterol; Female; Fluorobenzenes; Heart; Heart Rate; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocardial Ischemia; Myocardial Reperfusion Injury; Myocardium; Neutrophil Infiltration; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Peroxidase; Pravastatin; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Swine | 2005 |
Rosuvastatin, a new HMG-CoA reductase inhibitor, reduces the colonic inflammatory response in dextran sulfate sodium-induced colitis in mice.
Topics: Animals; Colitis; Colon; Cyclic N-Oxides; Dextran Sulfate; Female; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammatory Bowel Diseases; Mice; Mice, Inbred BALB C; Nitric Oxide Synthase Type III; Peroxidase; Pyrimidines; RNA, Messenger; Rosuvastatin Calcium; Sulfonamides; Thiobarbituric Acid Reactive Substances; Tumor Necrosis Factor-alpha | 2006 |